A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life
NCT ID: NCT04228757
Last Updated: 2020-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
130 participants
INTERVENTIONAL
2019-06-28
2020-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms
NCT06787443
The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial
NCT07210229
Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women
NCT05813067
Phytoserms for Menopause Symptoms and Age-Associated Memory Decline
NCT01723917
One Week Clinical Study in Subjects With Menopausal Symptoms
NCT06794021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Investigational Herbal Blend
A phytoestrogen herbal blend
phytoestrogen herbal blend
phytoestrogen herbal blend
Placebo
Tablet without active ingredients
Placebo
Tablet without active ingredients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
phytoestrogen herbal blend
phytoestrogen herbal blend
Placebo
Tablet without active ingredients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Report experiencing moderate to severe menopausal symptoms, characterized as including all of the following:
* Total Score of 11 or greater on the Greene Climacteric Scale (GCS) Questionnaire
* Self-reported frequent hot flashes experienced (estimated minimum of 28 during the past week, or an average of a minimum of 4 in a typical day)
* Absence of a regular menstrual cycle, defined as either: an irregular cycle for at least 6 months, or the absence of menses for 3 or more months
* Agreement to maintain current level of physical activity throughout the study period
* Willingness and ability to follow the procedures of the study
* Willingness and ability to provide informed consent
Exclusion Criteria
* Participant who has had both ovaries removed
* Women who are pregnant, breastfeeding, or planning on becoming pregnant during the course of the study
* A history of breast cancer or a positive mammogram
* A history of uterine cancer or an abnormal pap smear
* Abnormal vaginal bleeding (not related to menstrual irregularity)
* Liver disease
* A history of clinically diagnosed depression that a medical professional recommended should be medically treated
* A history of clinically diagnosed hypertension (systolic of 140 mmHg or greater or diastolic of 90 mmHg or greater)
* Hyperthyroidism determined by thyroid stimulating hormone (TSH) screening
* Any unstable medical condition as determined by the Principal Investigator (PI)
* Any significant clinical or laboratory abnormality identified by the PI
* Any change in the use of dietary supplements in the 2-month prior to enrollment
* The use of any product indicated for menopause symptoms in the 2 months prior to enrollment including: prescription drugs (e.g. estrogen/progestins), over-the-counter supplements (e.g. black cohosh, soy isoflavones, evening primrose oil, phytoestrogens, etc), or a significant change in diet to include more soy foods.
* The use of any psychiatric drugs in the 6 months prior to enrolling
* Self-reported abuse of drugs or alcohol
* Any smoking of cigarettes, vaping or e-cigarettes, or consumption of other tobacco products within the past 6 months
* Planned donation of blood during or up to 30 days after completion of the study
* An allergy to any ingredient in the herbal blend product or placebo
* A sensitivity to botanical extracts
* Previous participation in a clinical research study less than 30 days prior to randomization to a treatment group
* Any other condition that in the investigator's opinion may adversely affect the participant's ability to complete the study, or may pose a significant risk to the participant
40 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ObvioHealth
INDUSTRY
i-Health, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Parth Shah, MD
Role: PRINCIPAL_INVESTIGATOR
ObvioHealth
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ObvioHealth
Orlando, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein Fn, Heiman JR, Henderson VW, Hodis HN, Karas RH, Lobo RA, Manson JE, Reid RL, Schmidt PJ, Stuenkel CA; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008 Jul-Aug;15(4 Pt 1):584-602. doi: 10.1097/gme.0b013e31817b076a.
Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321.
Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD001395. doi: 10.1002/14651858.CD001395.pub4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBVIO-DSM-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.